Ask about this productRelated genes to: TL1A antibody
- Gene:
- TNFSF15 NIH gene
- Name:
- TNF superfamily member 15
- Previous symbol:
- -
- Synonyms:
- TL1, VEGI, TL1A, VEGI192A, MGC129934, MGC129935
- Chromosome:
- 9q32
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-04
- Date modifiied:
- 2017-03-02
Related products to: TL1A antibody
Related articles to: TL1A antibody
- Tumor necrosis factor-like cytokine 1A (TL1A, TNFSF15) is a profibrotic and proinflammatory cytokine. Experimental evidence implicates TL1A-mediated interactions in interstitial lung disease (ILD); such interactions are disrupted by decoy receptor 3 (DcR3) binding to TL1A. We examined the potential clinical value of circulating TL1A and DcR3 levels in systemic sclerosis (SSc). - Source: PubMed
Publication date: 2026/08/20
Poulia VassilikiVlachogiannis Nikolaos IAvdi Aikaterini-ParaskeviBournia Vasiliki-KalliopiBamias GeorgeTektonidou Maria GSfikakis Petros PPanopoulos Stylianos - Ulcerative colitis (UC) and psoriasis (PS) are both chronic inflammatory disorders that frequently occur together in clinical settings. Nevertheless, the common genetic basis and biological mechanisms underlying this comorbidity remain insufficiently understood. - Source: PubMed
Publication date: 2026/08/11
Liu GuoWu NaLuo QinghuaHu Siyao - Osteoarthritis (OA) is characterized by cartilage degeneration, oxidative stress, and chondrocyte senescence. This study investigated whether TL1A promotes OA through ENO1-associated redox, senescence and PI3K-AKT signaling mechanisms. - Source: PubMed
Publication date: 2026/08/07
Gao XiangLi JuntanYin ChangyuLi KaiGao YuyangZhang ZihaoLi XuSun Xun - Therapeutic blocking antibodies against TNF-like cytokine 1A (TL1A) are emerging as one of the most compelling targets in inflammatory bowel disease (IBD). Preliminary phase 2 studies using TL1A-blocking antibodies have demonstrated some of the highest response rates seen in UC and CD. As the field waits for definitive phase 3 study results, the first of which are expected this summer, mechanistic data continue to expand the biological scope of TL1A in IBD. - Source: PubMed
Publication date: 2026/08/06
Pires SilviaYang WeiLongman Randy S - The TNF‑like cytokine TL1A is a key regulator of immune responses through engagement of its receptor, death receptor 3 (DR3), and has emerged as a therapeutic target in inflammatory diseases. Prevailing models propose that TL1A binding initiates recruitment of adaptor proteins to DR3, leading to downstream signaling. Here, we investigated proximal DR3 signaling events and found that the adaptor proteins TRADD and TRAF2 associate with DR3 independently of TL1A stimulation in both TF‑1 cells and primary human CD4+ T cells. In contrast, TL1A stimulation was strictly required for activation of NF‑κB signaling, including IκBα degradation and downstream ubiquitination events. These findings indicate that DR3 can exist in a preassembled adaptor complex prior to ligand engagement and suggest a revised model in which TL1A binding confers signaling competence rather than initiating adaptor recruitment. We propose a structurally informed, hypothesis‑generating model in which ligand engagement promotes higher‑order organization of prebound signaling components to enable downstream signal transduction. Together, our results refine current understanding of TL1A/DR3 signaling by decoupling adaptor assembly from ligand‑dependent signal activation. - Source: PubMed
Sun WeiyongJohnson Bryce GVeerasubramanian Praveen KRockwell KristinDickinson Theresa ASommese Ruth FKarlsson Fridrik J